Summary

The global irritable bowel syndrome (IBS) treatment market is experiencing notable growth, driven by rising awareness, advancements in therapeutic research, and the growing adoption of digital health tools. IBS, a functional gastrointestinal disorder, presents symptoms such as abdominal pain, bloating, constipation, and diarrhea. With significant developments in diagnosis, medication, and holistic treatment programs, the IBS treatment Analysis is witnessing a transformative phase.

Market Insights

The IBS treatment market is projected to expand from US$ 4 Bn in 2025 to US$ 7.54 Bn by 2032, registering a strong compound annual growth rate (CAGR) of 9.48%. Growing demand for effective therapies and increased patient consultations have accelerated market expansion. Digital symptom tracking, advanced diagnostics, and combination therapies are redefining treatment delivery and patient management.

Clinical interest in novel therapies such as fecal microbiota transplantation (FMT), gut-brain axis medication, and microbiome-based treatments has also significantly increased. Furthermore, ongoing studies in gut health and gastrointestinal diagnostics are aiding the creation of personalized treatment plans tailored to individual needs.

Market Drivers

The market's growth trajectory is shaped by several key factors:

• Rising Global Prevalence of IBS: Affecting approximately 10% to 15% of the population, IBS is increasingly recognized as a major global health concern.

• Increased Awareness and Consultation Rates: Awareness campaigns by health organizations and better public education on IBS symptoms have led to an upsurge in diagnosis and treatment-seeking behavior.

• Advancement in Therapies: New medications, extended-release formulations like Linaclotide, and targeted antibiotics are providing patients with more effective relief and improved outcomes.

• Digital Health Integration: Adoption of mobile apps and virtual consultations is enhancing treatment accessibility and symptom monitoring.

• Growth in Personalized Medicine: Gut-brain axis research is fueling customized treatment options, improving both compliance and efficacy.

Business Opportunity

The intensified focus on research and development in IBS treatment is fostering business opportunities across the pharmaceutical and biotechnology sectors. Global investment in gastrointestinal disorders is increasing, with a surge in the development of microbiome-targeted drugs and combination therapies.

Retail pharmacies are emerging as a vital distribution channel, accounting for a large share of IBS medication sales. Their strategic expansion, integration of digital services, and growing presence in emerging economies further amplify accessibility and convenience for patients.

Regional Analysis

North America remains at the forefront of the IBS treatment market, propelled by advanced healthcare infrastructure, insurance coverage, and robust R&D initiatives. The region is also witnessing rapid adoption of digital solutions and targeted therapies, such as Linaclotide and Rifaximin.

Asia Pacific is anticipated to be the fastest-growing region during the forecast period. Countries like Japan, China, and India are implementing nationwide awareness campaigns, integrating digital diagnostics, and improving access to healthcare. This is contributing to strong demand for innovative IBS treatment options. Government initiatives and increasing healthcare expenditure in the region are further driving growth.

Key Players

Prominent players in the IBS treatment market are focusing on product development, strategic collaborations, and integrated care models. Companies are expanding their portfolio to cater to unmet needs and improve patient outcomes.

Leading companies include:

• Takeda Pharmaceutical Company Limited

• Pfizer Inc.

• Abbott Laboratories

• Novartis AG

• AstraZeneca PLC

• Ironwood Pharmaceuticals Inc.

• Allergan Plc

• Bausch Health Companies Inc.

• GlaxoSmithKline Plc

• Lexicon Pharmaceuticals Inc.

• Sucampo Pharmaceuticals Inc.

Recent developments such as the launch of India’s first IBS integrated care plan and acquisitions of companies working on integrin therapies are setting the stage for sustained market expansion.

Market Segmentation

By Product

• Fiber Supplements

• Anti-Diarrheal

• Anticholinergic and Antispasmodic

• Antidepressants

• Antibiotics

• Alosetron

• Lubiprostone

• Linaclotide

• NHE3 Inhibitors

By Indication

• IBS with Constipation (IBS-C)

• IBS with Diarrhoea (IBS-D)

• IBS with Alternating Constipation and Diarrhoea

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Drug Stores

• Online Pharmacies and Stores

• Hypermarkets and Supermarkets

By Region

• North America

• Europe

• East Asia

• South Asia and Oceania

• Latin America

• Middle East and Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Irritable Bowel Syndrome Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Irritable Bowel Syndrome Treatment Market Outlook, 2019-2032
3.1. Global Irritable Bowel Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032
3.1.1. Key Highlights
3.1.1.1. Fiber Supplements
3.1.1.2. Anti-Diarrheal
3.1.1.3. Anticholinergic and Antispasmodic
3.1.1.4. Antidepressant
3.1.1.5. Antibiotics Antibiotics
3.1.1.6. Alosetron
3.1.1.7. Lubiprostone
3.1.1.8. Linaclotide
3.1.1.9. NHE3
3.2. Global Irritable Bowel Syndrome Treatment Market Outlook, by Indication, Value (US$ Bn), 2019-2032
3.2.1. Key Highlights
3.2.1.1. Irritable Bowel Syndrome with Constipation
3.2.1.2. Irritable Bowel Syndrome with Diarrhoea
3.2.1.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhoea
3.3. Global Irritable Bowel Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
3.3.1. Key Highlights
3.3.1.1. Hospital Pharmacies
3.3.1.2. Retail Pharmacies
3.3.1.3. Drug Stores
3.3.1.4. Online Pharmacies and Stores
3.3.1.5. Hypermarkets and Supermarkets
3.4. Global Irritable Bowel Syndrome Treatment Market Outlook, by Region, Value (US$ Bn), 2019-2032
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Irritable Bowel Syndrome Treatment Market Outlook, 2019-2032
4.1. North America Irritable Bowel Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032
4.1.1. Key Highlights
4.1.1.1. Fiber Supplements
4.1.1.2. Anti-Diarrheal
4.1.1.3. Anticholinergic and Antispasmodic
4.1.1.4. Antidepressant
4.1.1.5. Antibiotics Antibiotics
4.1.1.6. Alosetron
4.1.1.7. Lubiprostone
4.1.1.8. Linaclotide
4.1.1.9. NHE3
4.2. North America Irritable Bowel Syndrome Treatment Market Outlook, by Indication, Value (US$ Bn), 2019-2032
4.2.1. Key Highlights
4.2.1.1. Irritable Bowel Syndrome with Constipation
4.2.1.2. Irritable Bowel Syndrome with Diarrhoea
4.2.1.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhoea
4.3. North America Irritable Bowel Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
4.3.1. Key Highlights
4.3.1.1. Hospital Pharmacies
4.3.1.2. Retail Pharmacies
4.3.1.3. Drug Stores
4.3.1.4. Online Pharmacies and Stores
4.3.1.5. Hypermarkets and Supermarkets
4.4. North America Irritable Bowel Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
4.4.1. Key Highlights
4.4.1.1. U.S. Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
4.4.1.2. U.S. Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
4.4.1.3. U.S. Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
4.4.1.4. Canada Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
4.4.1.5. Canada Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
4.4.1.6. Canada Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Irritable Bowel Syndrome Treatment Market Outlook, 2019-2032
5.1. Europe Irritable Bowel Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032
5.1.1. Key Highlights
5.1.1.1. Fiber Supplements
5.1.1.2. Anti-Diarrheal
5.1.1.3. Anticholinergic and Antispasmodic
5.1.1.4. Antidepressant
5.1.1.5. Antibiotics Antibiotics
5.1.1.6. Alosetron
5.1.1.7. Lubiprostone
5.1.1.8. Linaclotide
5.1.1.9. NHE3
5.2. Europe Irritable Bowel Syndrome Treatment Market Outlook, by Indication, Value (US$ Bn), 2019-2032
5.2.1. Key Highlights
5.2.1.1. Irritable Bowel Syndrome with Constipation
5.2.1.2. Irritable Bowel Syndrome with Diarrhoea
5.2.1.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhoea
5.3. Europe Irritable Bowel Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
5.3.1. Key Highlights
5.3.1.1. Hospital Pharmacies
5.3.1.2. Retail Pharmacies
5.3.1.3. Drug Stores
5.3.1.4. Online Pharmacies and Stores
5.3.1.5. Hypermarkets and Supermarkets
5.4. Europe Irritable Bowel Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
5.4.1. Key Highlights
5.4.1.1. Germany Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
5.4.1.2. Germany Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
5.4.1.3. Germany Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.4. U.K. Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
5.4.1.5. U.K. Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
5.4.1.6. U.K. Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.7. France Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
5.4.1.8. France Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
5.4.1.9. France Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.10. Italy Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
5.4.1.11. Italy Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
5.4.1.12. Italy Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.13. Turkey Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
5.4.1.14. Turkey Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
5.4.1.15. Turkey Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.16. Russia Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
5.4.1.17. Russia Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
5.4.1.18. Russia Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.19. Rest of Europe Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
5.4.1.20. Rest of Europe Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
5.4.1.21. Rest of Europe Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Irritable Bowel Syndrome Treatment Market Outlook, 2019-2032
6.1. Asia Pacific Irritable Bowel Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032
6.1.1. Key Highlights
6.1.1.1. Fiber Supplements
6.1.1.2. Anti-Diarrheal
6.1.1.3. Anticholinergic and Antispasmodic
6.1.1.4. Antidepressant
6.1.1.5. Antibiotics Antibiotics
6.1.1.6. Alosetron
6.1.1.7. Lubiprostone
6.1.1.8. Linaclotide
6.1.1.9. NHE3
6.2. Asia Pacific Irritable Bowel Syndrome Treatment Market Outlook, by Indication, Value (US$ Bn), 2019-2032
6.2.1. Key Highlights
6.2.1.1. Irritable Bowel Syndrome with Constipation
6.2.1.2. Irritable Bowel Syndrome with Diarrhoea
6.2.1.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhoea
6.3. Asia Pacific Irritable Bowel Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
6.3.1. Key Highlights
6.3.1.1. Hospital Pharmacies
6.3.1.2. Retail Pharmacies
6.3.1.3. Drug Stores
6.3.1.4. Online Pharmacies and Stores
6.3.1.5. Hypermarkets and Supermarkets
6.4. Asia Pacific Irritable Bowel Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
6.4.1. Key Highlights
6.4.1.1. China Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
6.4.1.2. China Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
6.4.1.3. China Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.4. Japan Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
6.4.1.5. Japan Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
6.4.1.6. Japan Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.7. South Korea Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
6.4.1.8. South Korea Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
6.4.1.9. South Korea Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.10. India Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
6.4.1.11. India Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
6.4.1.12. India Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.13. Southeast Asia Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
6.4.1.14. Southeast Asia Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
6.4.1.15. Southeast Asia Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.16. Rest of Asia Pacific Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
6.4.1.17. Rest of Asia Pacific Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
6.4.1.18. Rest of Asia Pacific Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Irritable Bowel Syndrome Treatment Market Outlook, 2019-2032
7.1. Latin America Irritable Bowel Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032
7.1.1. Key Highlights
7.1.1.1. Fiber Supplements
7.1.1.2. Anti-Diarrheal
7.1.1.3. Anticholinergic and Antispasmodic
7.1.1.4. Antidepressant
7.1.1.5. Antibiotics Antibiotics
7.1.1.6. Alosetron
7.1.1.7. Lubiprostone
7.1.1.8. Linaclotide
7.1.1.9. NHE3
7.2. Latin America Irritable Bowel Syndrome Treatment Market Outlook, by Indication, Value (US$ Bn), 2019-2032
7.2.1. Key Highlights
7.2.1.1. Irritable Bowel Syndrome with Constipation
7.2.1.2. Irritable Bowel Syndrome with Diarrhoea
7.2.1.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhoea
7.3. Latin America Irritable Bowel Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
7.3.1. Key Highlights
7.3.1.1. Hospital Pharmacies
7.3.1.2. Retail Pharmacies
7.3.1.3. Drug Stores
7.3.1.4. Online Pharmacies and Stores
7.3.1.5. Hypermarkets and Supermarkets
7.4. Latin America Irritable Bowel Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
7.4.1. Key Highlights
7.4.1.1. Brazil Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
7.4.1.2. Brazil Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
7.4.1.3. Brazil Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
7.4.1.4. Mexico Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
7.4.1.5. Mexico Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
7.4.1.6. Mexico Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
7.4.1.7. Argentina Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
7.4.1.8. Argentina Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
7.4.1.9. Argentina Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
7.4.1.10. Rest of Latin America Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
7.4.1.11. Rest of Latin America Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
7.4.1.12. Rest of Latin America Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Irritable Bowel Syndrome Treatment Market Outlook, 2019-2032
8.1. Middle East & Africa Irritable Bowel Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032
8.1.1. Key Highlights
8.1.1.1. Fiber Supplements
8.1.1.2. Anti-Diarrheal
8.1.1.3. Anticholinergic and Antispasmodic
8.1.1.4. Antidepressant
8.1.1.5. Antibiotics Antibiotics
8.1.1.6. Alosetron
8.1.1.7. Lubiprostone
8.1.1.8. Linaclotide
8.1.1.9. NHE3
8.2. Middle East & Africa Irritable Bowel Syndrome Treatment Market Outlook, by Indication, Value (US$ Bn), 2019-2032
8.2.1. Key Highlights
8.2.1.1. Irritable Bowel Syndrome with Constipation
8.2.1.2. Irritable Bowel Syndrome with Diarrhoea
8.2.1.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhoea
8.3. Middle East & Africa Irritable Bowel Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
8.3.1. Key Highlights
8.3.1.1. Hospital Pharmacies
8.3.1.2. Retail Pharmacies
8.3.1.3. Drug Stores
8.3.1.4. Online Pharmacies and Stores
8.3.1.5. Hypermarkets and Supermarkets
8.4. Middle East & Africa Irritable Bowel Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
8.4.1. Key Highlights
8.4.1.1. GCC Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
8.4.1.2. GCC Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
8.4.1.3. GCC Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1.4. South Africa Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
8.4.1.5. South Africa Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
8.4.1.6. South Africa Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1.7. Egypt Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
8.4.1.8. Egypt Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
8.4.1.9. Egypt Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1.10. Nigeria Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
8.4.1.11. Nigeria Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
8.4.1.12. Nigeria Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1.13. Rest of Middle East & Africa Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
8.4.1.14. Rest of Middle East & Africa Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032
8.4.1.15. Rest of Middle East & Africa Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Product vs Distribution Channel Heatmap
9.2. Manufacturer vs Distribution Channel Heatmap
9.3. Company Market Share Analysis, 2025
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Takeda Pharmaceutical Company Limited
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Pfizer, Inc.
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Abbott Laboratories
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Novartis AG
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. AstraZeneca PLC
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Ironwood Pharmaceuticals Inc. and Allergan Plc
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Bausch Health Companies Inc.
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. GlaxoSmithKline Plc.
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Lexicon Pharmaceuticals Inc.
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Sucampo Pharmaceuticals Inc.
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development

10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations